
AVROBIO AVRO
Quarterly report 2025-Q3
added 11-06-2025
AVROBIO Total Non Current Liabilities 2011-2025 | AVRO
Annual Total Non Current Liabilities AVROBIO
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 276 K | 484 K | 689 K | 27.5 M | 9.09 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 27.5 M | 276 K | 7.61 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
25.6 M | $ 4.89 | 3.82 % | $ 812 M | ||
|
Aclaris Therapeutics
ACRS
|
5.95 M | $ 3.25 | -0.15 % | $ 251 M | ||
|
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | ||
|
Aptevo Therapeutics
APVO
|
5 M | $ 1.06 | -6.19 % | $ 293 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Ascendis Pharma A/S
ASND
|
101 M | $ 217.87 | -1.16 % | $ 5 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.18 | -2.93 % | $ 7.65 B | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
BioVie
BIVI
|
62.5 K | $ 1.38 | -4.61 % | $ 2.04 M | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
23.6 M | - | -15.15 % | $ 60.3 M | ||
|
BioNTech SE
BNTX
|
341 M | $ 93.77 | -1.09 % | $ 27.2 B | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | ||
|
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | ||
|
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 26.05 | 3.07 % | $ 1.26 B | ||
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | ||
|
Anika Therapeutics
ANIK
|
26.1 M | $ 9.58 | 0.21 % | $ 140 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.63 M | $ 0.27 | -3.93 % | $ 588 M | ||
|
Catalyst Biosciences
CBIO
|
981 K | $ 13.91 | -1.31 % | $ 916 M | ||
|
Arena Pharmaceuticals
ARNA
|
52.2 M | - | -6.81 % | $ 3.04 B | ||
|
Athersys
ATHX
|
5.4 M | - | 3.77 % | $ 22.4 M | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | ||
|
Axon Enterprise
AXON
|
107 M | $ 548.94 | -2.72 % | $ 41.6 B | ||
|
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
42.1 M | $ 2.36 | 2.64 % | $ 14.8 M | ||
|
AstraZeneca PLC
AZN
|
30.8 B | $ 91.2 | 1.53 % | $ 96.9 B | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
374 M | - | 0.49 % | $ 251 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
802 M | $ 11.36 | -1.52 % | $ 735 M | ||
|
Biogen
BIIB
|
9.03 B | $ 173.9 | -0.12 % | $ 25.3 B | ||
|
Celldex Therapeutics
CLDX
|
17.3 M | $ 27.0 | -1.87 % | $ 1.74 M | ||
|
Abeona Therapeutics
ABEO
|
6.69 M | $ 5.08 | -5.32 % | $ 109 M | ||
|
ADiTx Therapeutics
ADTX
|
858 K | $ 1.68 | -25.0 % | $ 22.1 K | ||
|
Cellectar Biosciences
CLRB
|
422 K | $ 3.39 | -6.35 % | $ 41.4 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
48 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
22.3 M | - | -7.31 % | $ 87 M | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Завод ДИОД
DIOD
|
89.5 M | - | - | - | ||
|
Фармсинтез
LIFE
|
13.2 M | - | - | - |